{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T05:10:24Z","timestamp":1784005824786,"version":"3.55.0"},"reference-count":17,"publisher":"BMJ","issue":"6","license":[{"start":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T00:00:00Z","timestamp":1655856000000},"content-version":"unspecified","delay-in-days":21,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Erasmus MC Foundation","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2022,6,8]]},"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Malignant peritoneal mesothelioma (MPM) is a rare, aggressive tumour arising primarily from the peritoneum. The only potentially curative treatment is cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC). However, the majority of patients are not eligible to undergo this treatment. The benefit of systemic treatment for these patients is limited at the cost of considerable morbidity. Hence, there is a need for appropriate palliative treatment options for patients with MPM. As MPM rarely disseminates outside the abdominal cavity, these patients might benefit from local treatment. A higher, more effective dose of chemotherapy can directly be delivered at the site of the disease. Systemic uptake will be limited, likely resulting in less toxicity. The aim of the INTERACT MESO trial is to determine the maximum tolerable dose of intraperitoneal paclitaxel monotherapy in patients with MPM. Secondary endpoints are to assess safety and toxicity, feasibility and the pharmacokinetic profile of this treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>The INTERACT MESO trial is a prospective, open-label, single-centre, phase I study with a classic three-plus-three dose escalation design. The study population consists of adult patients with primary MPM, without extra-abdominal disease, who are not eligible to undergo CRS-HIPEC. According to standard of care work-up for CRS-HIPEC, patients will undergo diagnostic laparoscopy to determine the feasibility of CRS-HIPEC. In case CRS-HIPEC is not considered feasible, a peritoneal port-a-cath (PAC) system will be placed. Through this PAC, 8\u201316 weekly cycles of intraperitoneal chemotherapy will be administered.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>The Central Committee on Research Involving Human Subjects (CCMO, The Hague, The Netherlands) and the Medical Research Ethics Committee (METC, Rotterdam, The Netherlands) have granted permission to carry out this study protocol. The results of this trial will be submitted for publication in a peer-reviewed scientific journal.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>NL9718. EudraCT: 2021-003637-11.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2022-062907","type":"journal-article","created":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T12:06:03Z","timestamp":1655899563000},"page":"e062907","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":6,"title":["Intraperitoneal paclitaxel for patients with primary malignant peritoneal mesothelioma: a phase I\/II dose escalation and safety study\u2014INTERACT MESO"],"prefix":"10.1136","volume":"12","author":[{"given":"Job P","family":"van Kooten","sequence":"first","affiliation":[{"name":"Department of Surgical Oncology, Erasmus MC Kanker Instituut, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4304-3022","authenticated-orcid":false,"given":"Michelle V","family":"Dietz","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Erasmus MC Kanker Instituut, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels A D","family":"Guchelaar","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra R M","family":"Brandt-Kerkhof","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Erasmus MC Kanker Instituut, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stijn L W","family":"Koolen","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands"},{"name":"Department of Pharmacy, Erasmus MC Cancer Institute, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacobus W A","family":"Burger","sequence":"additional","affiliation":[{"name":"Department of Surgery, Catharina Hospital, Eindhoven, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron H J","family":"Mathijssen","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelis","family":"Verhoef","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Erasmus MC Kanker Instituut, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim G J V","family":"Aerts","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine, Erasmus MC Kanker Instituut, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva V E","family":"Madsen","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Erasmus MC Kanker Instituut, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,6,22]]},"reference":[{"key":"2025121410423070000_12.6.e062907.1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-019-07803-z"},{"key":"2025121410423070000_12.6.e062907.2","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-014-3978-x"},{"key":"2025121410423070000_12.6.e062907.3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.23.9640"},{"key":"2025121410423070000_12.6.e062907.4","doi-asserted-by":"publisher","DOI":"10.3816\/CLC.2005.n.020"},{"key":"2025121410423070000_12.6.e062907.5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.2868"},{"key":"2025121410423070000_12.6.e062907.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2008.08.013"},{"key":"2025121410423070000_12.6.e062907.7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32714-8"},{"key":"2025121410423070000_12.6.e062907.8","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0218-0"},{"key":"2025121410423070000_12.6.e062907.9","doi-asserted-by":"publisher","DOI":"10.4251\/wjgo.v2.i2.109"},{"key":"2025121410423070000_12.6.e062907.10","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1200\/JCO.1992.10.9.1485","article-title":"Phase i trial of intraperitoneal taxol: a gynecoloic oncology group study","volume":"10","author":"Markman","year":"1992","journal-title":"J Clin Oncol"},{"key":"2025121410423070000_12.6.e062907.11","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1200\/JCO.1995.13.12.2961","article-title":"Phase I feasibility and pharmacologic study of Weekly intraperitoneal paclitaxel: a gynecologic oncology group pilot study","volume":"13","author":"Francis","year":"1995","journal-title":"J Clin Oncol"},{"key":"2025121410423070000_12.6.e062907.12","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1200\/JCO.1998.16.8.2620","article-title":"Phase II trial of intraperitoneal paclitaxel in carcinoma of the ovary, tube, and peritoneum: a gynecologic oncology group study","volume":"16","author":"Markman","year":"1998","journal-title":"J Clin Oncol"},{"key":"2025121410423070000_12.6.e062907.13","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.suronc.2020.01.009","article-title":"Unusually favorable outcome of 6 consecutive patients with diffuse malignant peritoneal mesothelioma treated with repeated doses of intraperitoneal paclitaxel. A case series","volume":"33","author":"Sugarbaker","year":"2020","journal-title":"Surg Oncol"},{"key":"2025121410423070000_12.6.e062907.14","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr.2018.08.03"},{"key":"2025121410423070000_12.6.e062907.15","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/j.ejso.2017.01.009","article-title":"Long-term regional chemotherapy for patients with epithelial malignant peritoneal mesothelioma results in improved survival","volume":"43","author":"Sugarbaker","year":"2017","journal-title":"Eur J Surg Oncol"},{"key":"2025121410423070000_12.6.e062907.16","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e7586"},{"key":"2025121410423070000_12.6.e062907.17","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-034508","article-title":"Concomitant intraperitoneal and systemic chemotherapy for extensive peritoneal metastases of colorectal origin: protocol of the multicentre, open-label, phase I, dose-escalation interact trial","volume":"9","author":"de Boer","year":"2019","journal-title":"BMJ Open"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2022-062907","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T18:42:39Z","timestamp":1765737759000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2022-062907"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":17,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,6,22]]},"published-print":{"date-parts":[[2022,6]]}},"alternative-id":["10.1136\/bmjopen-2022-062907"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2022-062907","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6]]}}}